REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide Library

Pinealon

EDR peptide / Glu-Asp-Arg

Longevity & Anti-Aging

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg) developed by Professor Vladimir Khavinson as part of the bioregulator peptide class, designed to target and normalize pineal gland function. It belongs to a family of ultrashort peptides theorized to penetrate cell nuclei and interact directly with DNA to regulate gene expression in specific tissue types. Primary research applications include circadian rhythm regulation, neuroprotection, and normalization of melatonin synthesis in aging populations.

Mechanism of Action

Synthetic tripeptide bioregulator that penetrates cell membranes and interacts with DNA in the promoter region of genes involved in neurodifferentiation. Promotes neuronal survival, reduces oxidative stress in brain tissue, and modulates circadian rhythm via pineal gland function.

Research Protocols

For research purposes only. Not medical advice.

Research protocols (Khavinson method) use 10-20mg orally or sublingually daily for 10-30 day cycles. Sublingual administration may improve bioavailability. Cycles repeated every 3-6 months.

Research Notes

Clinical Research Status

Pinealon has been studied primarily in Russian clinical research settings, with publications appearing in Russian biomedical journals and the St. Petersburg Institute of Bioregulation and Gerontology. Clinical studies in elderly patients have reported improvements in sleep quality, cognitive function, and normalization of melatonin cycling following oral or intranasal administration. It is registered and available as a dietary supplement in Russia but has not undergone Western regulatory review or FDA evaluation.

Key Published Findings

Research by Khavinson's group demonstrates that Pinealon can penetrate cell membranes and nuclear envelopes to interact with specific DNA sequences, potentially regulating gene expression related to pineal gland function. In vitro studies show the peptide promotes neuronal survival under oxidative stress conditions and normalizes circadian gene expression patterns. Animal studies indicate restoration of melatonin synthesis capacity in aged rats and improvement of learning and memory in models of accelerated aging.

Safety Profile

As a naturally occurring amino acid sequence found in human tissue, Pinealon is reported to have an excellent safety profile with no documented adverse effects in available clinical literature. The tripeptide structure is rapidly metabolized into constituent amino acids (glutamic acid, aspartic acid, arginine), minimizing accumulation risk. No drug interactions have been formally documented, though caution is theoretically warranted when combining with exogenous melatonin or other sleep-modulating compounds.

Comparison to Related Compounds

Pinealon differs from exogenous melatonin supplementation by theoretically restoring endogenous melatonin production capacity rather than simply replacing the hormone. Compared to the related Khavinson peptide Epithalon (which targets telomerase in the pineal gland), Pinealon focuses on functional normalization rather than cellular longevity mechanisms. Within the bioregulator peptide family, each compound is tissue-specific: Pinealon targets the pineal gland, Cortexin targets the brain cortex, and Retinalamin targets the retina.

Community Observations

Users typically report improved sleep onset latency and sleep quality within 1-2 weeks of sublingual or intranasal administration. Some users prefer Pinealon over exogenous melatonin due to the absence of morning grogginess and more natural-feeling sleep architecture. Sourcing is primarily limited to Russian pharmacies or specialized peptide suppliers, with quality verification being a common concern in the community.

Half-Life

~15-30 minutes

Reconstitution

N/A (typically oral/sublingual capsule)

Storage

Lyophilized

Room temperature. Protect from moisture.

Reconstituted

N/A (oral form)

US Legal Status

Research chemical (not FDA-approved)

Also Known As

EDR peptideGlu-Asp-Arg

PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer